News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 270043

Thursday, 08/11/2016 5:20:34 PM

Thursday, August 11, 2016 5:20:34 PM

Post# of 347009

BlackRock is smarter..



Next to take a step back and look at this from another angle. Blackrock was AstraZeneca's LARGEST shareholder as of May 22, 2014
http://www.reuters.com/article/us-astrazeneca-pfizer-blackrock-idUSBREA4L18R20140522

More interesting... would be BlackRock just bought a hell of a lot more AstraZeneca, reported yesterday Aug 10, 2016.

Blackrock Investment Management, LLC Buys A Lot More Astrazeneca PLC Common Stock (AZN) Stock In The Last Quarter
http://www.fidaily.com/blackrock-investment-management-llc-buys-a-lot-more-astrazeneca-plc-common-stock-azn-stock-in-the-last-quarter/257027/ted-blackburn

What does BlackRock know? Why did Blackrock sell down their holdings in PPHM leading up to Sept 2012 and all of a sudden increase their holdings immediately the following quarter...

I have some ideas and who else could keep a stock like PPHM in such a small trading range? Could it be Blackrock .... could have some party filed to the SEC to acquire a large amount of shares and keep it all silent as possibly, legally allowed?

The puzzle pieces have been floating out there and its easy to see that someone is accumulating big time.

How many times a month would Peregrine have talks with Broadridge to verify the holdings and locations of certain shares...

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y